title: p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
abstract: Oxaliplatin is an efficient chemotherapeutic agent used for the treatment of metastatic human colon cancer, but cancer cells are frequently resistant. The aim of this study was to analyse the underlying mechanisms in a panel of 10 human colorectal cancer cell lines submitted to a short (2h) oxaliplatin treatment period, accordingly to the usual therapeutic procedure in humans. Sensitivity to oxaliplatin was a characteristic of p53 wild-type colon cancer cells. In contrast, all p53-mutated cell lines had a high IC50 to oxaliplatin, with the exception of the V9P cell line. Exposure to oxaliplatin resulted in G0/G1 arrest in p53 wild-type cell lines, and in S phase in p53-mutated cell lines. In our treatment conditions, no DNA accumulation in sub G0/G1 phase, no caspase-3 activation nor PARP cleavage were detected after oxaliplatin treatment, except for the V9P cell line. The major role of the p53-p21 pathway in oxaliplatin sensitivity was confirmed in the p53 wild-type HCT116 cell line, using siRNA duplex, and knockdown of the TAp73 protein also enhanced resistance to oxaliplatin in this cell line. Surprisingly, siRNA duplex invalidation revealed a residual effect of the mutant p53 protein in p53-mutated cell lines. Persistent sensitivity to oxaliplatin of the p53-mutated V9P cell line was associated with oxalipatin-induced apoptosis but TAp73 was not the responsible alternative pathway.
authors.affiliation: INSERM U865, Lyon F-69372, France.
authors.forename: Florent
authors.initials: F
authors.lastname: Toscano
authors.forename: Béatrice
authors.initials: B
authors.lastname: Parmentier
authors.forename: Zineb El
authors.initials: ZE
authors.lastname: Fajoui
authors.forename: Yann
authors.initials: Y
authors.lastname: Estornes
authors.forename: Jean-Alain
authors.initials: JA
authors.lastname: Chayvialle
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Saurin
authors.forename: Jacques
authors.initials: J
authors.lastname: Abello
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001483:Base Sequence; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology*; D017931:DNA Primers; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D034741:RNA, Small Interfering; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D017931:DNA Primers; D009944:Organoplatinum Compounds; D034741:RNA, Small Interfering; D016159:Tumor Suppressor Protein p53; D000077150:Oxaliplatin